Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation.

Albano C, Smitz J, Camus M, Riethmüller-Winzen H, Van Steirteghem A, Devroey P

Fertility and sterility1 May 1997Cited by 150 (Europe PMC)

PMID9130900DOI10.1016/s0015-0282(97)81407-0PepBankPUB-09130900

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In women undergoing ovarian stimulation, FSH, LH, E2 and progesterone areas under the curve were similar with cetrorelix 0.25 and 0.5 mg.
In plain wordsIn women undergoing ovarian stimulation, hormone areas under the curve were similar with cetrorelix 0.25 and 0.5 mg.
Peptide
Cetrorelix
Outcome
Direction not reportedFSH, LH, E2 and progesterone area under the curve
Study
n = 62
Comparator
Cetrorelix 0.5 mg daily
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.25 mg daily · daily from day 6 of hMG through its last injectionAs given in this study (human).
Source sentences
Summary
Follicle-stimulating hormone, LH, E2, and P expressed as area under the curve were similar in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection.
Summary · context
In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively.
Summary · context
Seven patients received 0.1 mg of Cetrorelix.
Report a problemFND-0913090005
02HumanNon-randomized trialEfficacy outcome
In women undergoing controlled ovarian hyperstimulation, no premature LH surge occurred with cetrorelix 0.5 mg daily.
In plain wordsIn women undergoing ovarian stimulation, no premature LH surge occurred with cetrorelix 0.5 mg daily.
Peptide
Cetrorelix
Outcome
Not applicablePremature LH surge at 0.5 mg
Study
n = 32
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.5 mg daily · daily from day 6 of hMG through its last injectionAs given in this study (human).
Source sentences
Summary
No premature endogenous LH surge occurred in patients treated with 0.5 and 0.25 mg of Cetrorelix, and serum LH concentrations were maintained constantly low during the entire follicular phase in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection.
Summary · context
In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively.
Summary · context
Seven patients received 0.1 mg of Cetrorelix.
Report a problemFND-0913090001
03HumanNon-randomized trialEfficacy outcome
In women undergoing controlled ovarian hyperstimulation, cetrorelix 0.5 mg maintained constantly low LH throughout the follicular phase.
In plain wordsIn women undergoing ovarian stimulation, cetrorelix 0.5 mg maintained low LH throughout the follicular phase.
Peptide
Cetrorelix
Outcome
Not applicableFollicular LH concentrations at 0.5 mg
Study
n = 32
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.5 mg daily · daily from day 6 of hMG through its last injectionAs given in this study (human).
Source sentences
Summary
No premature endogenous LH surge occurred in patients treated with 0.5 and 0.25 mg of Cetrorelix, and serum LH concentrations were maintained constantly low during the entire follicular phase in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection.
Summary · context
In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively.
Summary · context
Seven patients received 0.1 mg of Cetrorelix.
Report a problemFND-0913090003
04HumanNon-randomized trialEfficacy outcome
In women undergoing controlled ovarian hyperstimulation, no premature LH surge occurred with cetrorelix 0.25 mg daily.
In plain wordsIn women undergoing ovarian stimulation, no premature LH surge occurred with cetrorelix 0.25 mg daily.
Peptide
Cetrorelix
Outcome
Not applicablePremature LH surge at 0.25 mg
Study
n = 30
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.25 mg daily · daily from day 6 of hMG through its last injectionAs given in this study (human).
Source sentences
Summary
No premature endogenous LH surge occurred in patients treated with 0.5 and 0.25 mg of Cetrorelix, and serum LH concentrations were maintained constantly low during the entire follicular phase in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection.
Summary · context
In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively.
Summary · context
Seven patients received 0.1 mg of Cetrorelix.
Report a problemFND-0913090002
05HumanNon-randomized trialEfficacy outcome
In women undergoing controlled ovarian hyperstimulation, cetrorelix 0.25 mg maintained constantly low LH throughout the follicular phase.
In plain wordsIn women undergoing ovarian stimulation, cetrorelix 0.25 mg maintained low LH throughout the follicular phase.
Peptide
Cetrorelix
Outcome
Not applicableFollicular LH concentrations at 0.25 mg
Study
n = 30
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.25 mg daily · daily from day 6 of hMG through its last injectionAs given in this study (human).
Source sentences
Summary
No premature endogenous LH surge occurred in patients treated with 0.5 and 0.25 mg of Cetrorelix, and serum LH concentrations were maintained constantly low during the entire follicular phase in both groups.
3 context sentences(design, population, supporting numbers)
Summary · context
In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection.
Summary · context
In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively.
Summary · context
Seven patients received 0.1 mg of Cetrorelix.
Report a problemFND-0913090004
06HumanNon-randomized trialEfficacy outcome
In women given cetrorelix 0.1 mg during ovarian stimulation, one of seven patients had a premature LH surge to 18 mIU/mL.
In plain wordsIn women given cetrorelix 0.1 mg during ovarian stimulation, one of seven patients had a premature LH surge to 18 mIU/mL.
Peptide
Cetrorelix
Outcome
IncreasePremature LH surge at 0.1 mg
Study
n = 7
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.1 mg daily · daily from day 6 of hMG through its last injectionAs given in this study (human).
Measurements
LH concentration at premature surge
18 mIU/mL
premature surge, 0.1 mg
patients with premature LH surge
1 patient
0.1 mg group, of 7 patients
Source sentences
Summary
A premature LH surge (18 mIU/mL; conversion factor to SI unit, 1.00) with a concomitant P rise (1.7 micrograms/L; conversion factor to SI unit, 3.180) occurred in one of the seven patients treated with 0.1 mg Cetrorelix; therefore, treatment with this dose was discontinued.
3 context sentences(design, population, supporting numbers)
Summary · context
In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection.
Summary · context
In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively.
Summary · context
Seven patients received 0.1 mg of Cetrorelix.
Report a problemFND-0913090006
07HumanNon-randomized trialEfficacy outcome
In women given cetrorelix 0.1 mg during ovarian stimulation, the patient with a premature LH surge also had progesterone rise to 1.7 micrograms/L.
In plain wordsIn women given cetrorelix 0.1 mg during ovarian stimulation, one patient's progesterone rose to 1.7 micrograms/L with a premature LH surge.
Peptide
Cetrorelix
Outcome
IncreaseProgesterone rise at 0.1 mg
Study
n = 1
Outcome group
Sex hormones and fertility · Endocrine and hormones
Studied dose
0.1 mg daily · daily from day 6 of hMG through its last injectionAs given in this study (human).
Measurements
Progesterone
1.7 micrograms/L
concomitant rise
Source sentences
Summary
A premature LH surge (18 mIU/mL; conversion factor to SI unit, 1.00) with a concomitant P rise (1.7 micrograms/L; conversion factor to SI unit, 3.180) occurred in one of the seven patients treated with 0.1 mg Cetrorelix; therefore, treatment with this dose was discontinued.
3 context sentences(design, population, supporting numbers)
Summary · context
In 69 patients COH was carried out with the association of hMG, starting on day 2 of the menstrual cycle, and a GnRH antagonist (Cetrorelix) was administered from day 6 of the hMG treatment (day 7 of the menstrual cycle) every day up to and including the last day of the hMG injection.
Summary · context
In 32 and 30 patients, 0.5 mg and 0.25 mg of Cetrorelix were administered, respectively.
Summary · context
Seven patients received 0.1 mg of Cetrorelix.
Report a problemFND-0913090007

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

Status unknownPhase 2/3Results postedNCT02823080

Outcome of Cetrotide Therapy for Management of Women at High-risk of Ovarian Hyperstimulation Syndrome

Benha Universityn = 48Oct 2014 to est. May 2017

Infertility

Trial page ClinicalTrials.govUpdated 30 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.